摘要
中成药中"一品多家"现象非常普遍。不同厂家的产品质量良莠不分,价格高低不一,疗效参差不齐。为确保广大患者获得优质的中成药,推动药品优质优价"健康国家战略",有必要针对当前现状,开展优质中成药评价标准研究。该文建立了以质量为核心的优质中成药评价标准,形成了从原料、生产、质控、再评价到其它竞争力的全链条评价策略,旨在揭示不同厂家产品的质量差异,评选出真正的优质产品。希望通过该标准的研究和应用为中成药科学合理的价格形成机制提供参考,为药品招标提供依据,引导中成药市场良性竞争,推动"健康中国2030"的实施。
"One drug was produced by many companies" is common in Chinese patent medicines. The quality and price of products from different manufacturers varies widely, and the efficacy is inconsistency. In order to ensure the quality of Chinese patent medicines and promote "Healthy national program" implementation, it is necessary to study the current status of Chinese patent medicines and carry out the evaluation criteria over quality as the core management of high grade Chinese patent medicines, which is set up to reflect the evaluation strategy and method of Chinese patent medicines from raw material, production, quality control, reevaluation and competitive power to the whole chain of brand construction. It aims to reveal the quality discrepancy from different manufacturers over the same Chinese patent medicines. The research and application will select a serials of high grade quality products, and provide reference basis for the scientific and reasonable price formation mechanism of Chinese patent medicines and purchasing drugs by centralized bidding, guide healthy competition in the market and promote the implementation of "healthy China 2030 program".
作者
刘艳
吁海超
章军
陈畅
程锦堂
宋宗华
刘安
LIU Yan;YU Hai-chao;ZHANG Jun;CHEN Chang;CHENG Jin-tang;SONG Zong-hua;LIU An(Institute of Chinese Materia Medica,China Academy of Chinese Medical Sciences,Belling 100700,China;Chinese Pharmacopoeia Commission,Beijing 100061,China)
出处
《中国中药杂志》
CAS
CSCD
北大核心
2018年第21期4356-4360,共5页
China Journal of Chinese Materia Medica
基金
国家自然科学基金项目(81703948)
国家中药标准化项目(G201703)
关键词
优质中成药
评价标准
质量
全链条评价
high grade Chinese patent medicine
evaluation criteria
quality
full chain evaluation
